Comparison between 0.25% bupivacaine and 0.375% ropivacaine in tranversus abdominis plane block for pain relief after total laproscopic hysterectomy operation

A comparative study of 0.25% bupivacaine and 0.375% ropivacaine in tranversus abdominis plane block for post operative analgesia in patients undergoing total laproscopic hysterectomy. - No

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/06/054000

Enrollment

Registered

2023-06-16

Start date

Unknown

Completion date

Unknown

Last updated

2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: Bupivacaine and Ropivacaine: 0.25% bupivacaine and 0.375% ropivacaine in tranversus abdominis plane block Control Intervention1: 0.375% ROPIVACAINE IN TRANSVERSUS ABDOMINIS PLANE BLOCK:

Eligibility

Inclusion criteria

Inclusion criteria: 1)Female patients of age beetween 18-60 years undergoing total laparoscopic hysterectomy. 2) Patient With ASA grade: I and II.

Exclusion criteria

Exclusion criteria: 1) patients not willing to participate in study. 2) Patients with coagulation abnormalities. 3) Patient with Local site skin infection. 4) Patients having hypersensitive reaction to any of the drugs being used.

Design outcomes

Primary

Measure	Time frame
Post operative analgesia in patients undergoing total laparascopic hysterectomyTimepoint: 1,2,4,6,12 HOUR	—

Secondary

Measure	Time frame
to compare quality of analgesia (VAS score) in patients undergoing total laparoscopic hysterectomyTimepoint: 1,2,4,6,12 HOUR	—

Countries

India

Contacts

Public ContactDr Vaibhav Girishkumar Vansola

Gujarat adani institute of medical sciences, bhuj

dr.jaldeep2527@gmail.com9537139646

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026